Mien Van Hoang, Ph.D.

Research Summary

Dr. Hoang is a research scientist. His main interest is in molecular signaling that regulates vascular abnormality in diabetic retinopathy with the goal of identifying a molecular target, which can correct vascular defects. His current research project focuses on answering a mysterious question: why are humans highly susceptible to diabetic retinopathy while rodents are not? By answering this question, he hopes to develop a rodent diabetic retinopathy model for testing drugs and for unraveling molecular mechanism that protects retinal vascular dysfunction.


1994: B.Sc., Biochemistry, First Class Honor, University of London, Royal Holloway College, England, UK

1998: Ph.D., Biochemistry and Molecular Biology, University of Leeds, England, UK

Postgraduate Training

2000: Fellowship, Welcome Trust Center for Cell Matrix Research, University of Manchester, England, UK

2010: Fellowship, Beth Israel Deaconess Medical Center and Harvard Medical School Center for Vascular Biology Research

Academic Appointments

2010-present: Instructor in Ophthalmology, Harvard Medical School

Professional Memberships

2010-present: Mass. Eye and Ear Alumni Association

2004-present: American Society for Cell Biology

1998-present: UK Biochemical Society


1991-1994: Driver Prize, University of London, Royal Holloway College

1994-1998: British Medical Research Council (MRC) Instant Award Studentship


Selected Publications

For a full publication list, please see his CV.

  1. Senger DR, Hoang MV, Kim KH, Li C, Cao S. Anti-inflammatory activity of Barleria lupulina: Identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells. J Ethnopharmacol. 2016 Dec 04; 193:397-407. 
  2. Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood. 2011 Feb 03; 117(5):1751-60.  
  3. Hoang MV, Nagy JA, Fox JE, Senger DR. Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis. PLoS One. 2010 Oct 25; 5(10):e13612. 
  4. Hoang MV, Smith LE, Senger DR. Moderate GSK-3ß inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis. 2010 Sep; 13(3):269-77. 
  5. Kosmidou C, Efstathiou NE, Hoang MV, Notomi S, Konstantinou EK, Hirano M, Takahashi K, Maidana DE, Tsoka P, Young L, Gragoudas ES, Olsen TW, Morizane Y, Miller JW, Vavvas DG. Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration. Sci Rep. 2018 Jan 11; 8(1):461. 

View a complete list of publications on pubmed.gov>>